Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ERYTHROMYCIN ETHYLSUCCINATE

2 general benefit · 2 not a benefit

Other products in the same Health Canada class (J01FA) — coverage varies; not interchangeable

  • Azithromycin (Zithromax): general benefit, Limited Use 549, Not a benefit
  • Clarithromycin (Biaxin XL): general benefit, Not a benefit
  • Erythromycin base (Erythromid): general benefit, Not a benefit
  • Erythromycin estolate (Ilosone): general benefit, Not a benefit

Novo-Rythro Ethyl Succinate · DIN 00605859 · 40mg/mL · oral liquid

General benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.Discontinued 2015-10-26 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Novo-Rythro Ethyl Succinate · DIN 00605859 Manufacturer: Novopharm Ltd.; listing date 1996-10-01 Daily cost (source): $1.0035 Health Canada: Cancelled post market since 2015-10-26 · brand NOVO-RYTHRO ETHYLSUCCINATE PWS · ATC J01FA01 ERYTHROMYCIN · form Powder for solution · route Oral · ingredients ERYTHROMYCIN (ERYTHROMYCIN ETHYLSUCCINATE) 200 MG/5ML · company Bioline laboratories inc. · schedule Prescription
Check this DIN again · Health Canada product record

Novo-Rythro Ethyl Succinate: Formulary list price $0.0669/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0669 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5603 · Verify on the e-Formulary ↗ (DIN 00605859)

Source record
DIN 00605859: Novo-Rythro Ethyl Succinate Raw flags: sec3=Y Item: 081212002; group id 24; item number 0039; lccId None; manufacturer id NOP Source form: O/L; strength: 40mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0669; ministry $0.0669 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00605859 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5603
Interchangeable products
EES-200 · DIN 00000299 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00605859
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.

Novo-Rythro Ethyl Succinate · DIN 00652318 · 80mg/mL · oral liquid

General benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.Discontinued 2015-10-26 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Novo-Rythro Ethyl Succinate · DIN 00652318 Manufacturer: Novopharm Ltd.; listing date 1996-10-01 Daily cost (source): $1.5195 Health Canada: Cancelled post market since 2015-10-26 · brand NOVO-RYTHRO ETHYLSUCCINATE PWR 400MG/5ML · ATC J01FA01 ERYTHROMYCIN · form Powder · route Oral · ingredients ERYTHROMYCIN (ERYTHROMYCIN ETHYLSUCCINATE) 400 MG/5ML · company Nutrition plus pharmacy ltd. · schedule Prescription
Check this DIN again · Health Canada product record

Novo-Rythro Ethyl Succinate: Formulary list price $0.1013/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1013 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6324 · Verify on the e-Formulary ↗ (DIN 00652318)

Source record
DIN 00652318: Novo-Rythro Ethyl Succinate Raw flags: sec3=Y Item: 081212009; group id 24; item number 0040; lccId None; manufacturer id NOP Source form: O/L; strength: 80mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1013; ministry $0.1013 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00652318 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6324
Interchangeable products
EES-400 · DIN 00453617 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00652318
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.

EES-200 · DIN 00000299 · 40mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-22 — choose a marketed DIN from the same-category list.Discontinued 2017-06-22 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-06-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
EES-200 · DIN 00000299 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Daily cost (source): $1.0035 Health Canada: Cancelled post market since 2017-06-22 · brand EES-200 · ATC J01FA01 ERYTHROMYCIN · form Powder for suspension · route Oral · ingredients ERYTHROMYCIN (ERYTHROMYCIN ETHYLSUCCINATE) 40 MG/ML · company Bio actif inc. · schedule Prescription
Check this DIN again · Health Canada product record

EES-200: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3698 · Verify on the e-Formulary ↗ (DIN 00000299)

Source record
DIN 00000299: EES-200 Raw flags: notABenefit=Y, sec3=Y Item: 081212002; group id 24; item number 0039; lccId None; manufacturer id ABB Source form: O/L; strength: 40mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00000299 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3698
Interchangeable products
Novo-Rythro Ethyl Succinate · DIN 00605859 · $0.0669
Shortage status: discontinued (2017-06-21, reported by AMDIPHARM LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00000299
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-06-22 — choose a marketed DIN from the same-category list.

EES-400 · DIN 00453617 · 80mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-22 — choose a marketed DIN from the same-category list.Discontinued 2017-06-22 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-06-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
EES-400 · DIN 00453617 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Daily cost (source): $1.5195 Health Canada: Cancelled post market since 2017-06-22 · brand EES-400 · ATC J01FA01 ERYTHROMYCIN · form Powder for suspension · route Oral · ingredients ERYTHROMYCIN (ERYTHROMYCIN ETHYLSUCCINATE) 400 MG/5ML · company Amdipharm limited · schedule Prescription
Check this DIN again · Health Canada product record

EES-400: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3172 · Verify on the e-Formulary ↗ (DIN 00453617)

Source record
DIN 00453617: EES-400 Raw flags: notABenefit=Y, sec3=Y Item: 081212009; group id 24; item number 0040; lccId None; manufacturer id ABB Source form: O/L; strength: 80mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00453617 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3172
Interchangeable products
Novo-Rythro Ethyl Succinate · DIN 00652318 · $0.1013
Shortage status: discontinued (2017-06-21, reported by AMDIPHARM LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00453617
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-06-22 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:12 Erythromycins) and how they are covered

Matched class: 08:12:12 Erythromycins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AZITHROMYCIN, CLARITHROMYCIN, ERYTHROMYCIN BASE, ERYTHROMYCIN ESTOLATE 08:12:12 Erythromycins

AZITHROMYCIN

· 28 products · Listed, not a benefit (6), General benefit (21), Limited Use, codes 549 (1) · strengths: 100mg/5mL, 200mg/5mL, 250mg, 600mg · O/L-15mL Pk, O/L-22.5mL Pk, O/L-37.5mL Pk, Tab

CLARITHROMYCIN

· 25 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 500mg, 125mg/5mL, 250mg/5mL, 250mg · ER Tab, Ped Gran, Susp, Tab

ERYTHROMYCIN BASE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ERYTHROMYCIN ESTOLATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:12
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

EES-200 · DIN 00000299 Shortage status: discontinued (2017-06-21, reported by AMDIPHARM LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00000299

Check this DIN again

EES-400 · DIN 00453617 Shortage status: discontinued (2017-06-21, reported by AMDIPHARM LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00453617

Check this DIN again

Other review policies

For EES-200, EES-400: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026